Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a High-Tech nebulizer tame severe asthma attacks faster?

NCT ID NCT05691218

Disease control Sponsor: Poitiers University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This study compares three ways to give inhaled asthma medication to adults having a moderate-to-severe asthma attack in the emergency department. One group receives the standard nebulizer treatment, another uses a vibrating mesh nebulizer, and a third uses the vibrating mesh nebulizer combined with heated, humidified high-flow oxygen. The goal is to see if the newer devices help patients improve faster and avoid hospitalization.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Beta-2 adrenergic agonist (bronchodilator) delivered via vibrating mesh nebulizer, with or without high-flow nasal cannula oxygen
What this could lead to
If effective, this approach could speed up recovery from asthma attacks, reduce hospital admissions, and improve outcomes for patients in the emergency department.
What could go wrong
This is a small, early-stage trial, so results may not be conclusive. The vibrating mesh device might not be more effective than standard nebulizers, and high-flow oxygen could cause discomfort or side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age equal or over 18 years * admitted in an Emergency Department with a clinical suspicion of acute exacerbation of asthma according to the Global Initiative for Asthma (GINA) criteria. * with at least one of the following criteria 60mn after a first treatment by beta-2 agonist adrenergic nebulization with 3 x 5 mg of terbutaline: * Respiratory rate over 22 breaths/min * Peak flow \< 50% of predictive normal value * SpO2 \< 95% in room air * Signs of severe asthma exacerbation (at least one criteria): Talks in word, Agitation, Sits hunched forwards, Accessory muscles in use * Free subject, without guardianship or curatorship or subordination * Patients benefiting from a Social Security scheme or benefiting from it through a third party * Informed consent signed by the patient after clear and honest information about the study Exclusion Criteria: * Acute exacerbation of asthma during the last 30 days * Clinical suspicion of acute exacerbation of asthma due to anaphylaxis, pneumothorax, pneumomediastinum, pneumonia or atelectasis. * At least ONE of the following serious signs: drowsiness, confusion, auscultatory silence * Clinical suspicion of another pathology that could explain the respiratory failure such as heart failure, laryngeal obstruction, pulmonary embolism, etc * Patients with neurological (Glasgow \< 13) or hemodynamical failure (Mean Arterial Pressure \< 65 mmHg) * contraindication to treatment with a beta-2-adrenergic agonist * History of hypersensitivity (allergy) to terbutaline or any of the constituents * Contraindication to OHD * Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, people assessed GIR1 or GIR 2 (AGGIR grid), adults under legal protection * Pregnant or breastfeeding women, Women at age to procreate and not using effective contraception

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute exacerbation of asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute asthma status asthmaticus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate asthma exacerbation Severe asthma exacerbation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital of Poitiers

    RECRUITING

    Poitiers, France, 86021, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.